- PR Newswire•4 days ago
ALBANY, N.Y., Nov. 29, 2016 /PRNewswire/ -- AMRI (AMRI) announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, Inc. which product has been in AMRI's portfolio through the required stages of development. Shire plc, is a leading global biotechnology company focused on developing and marketing innovative medicines for patients with rare diseases and other highly specialized conditions. The terms of the agreement are confidential. This is the second such multi-year agreement between AMRI and Shire, as AMRI has also been supplying a key neuroscience product to Shire. "This agreement builds on the long-standing development and manufacturing relationship between Shire and AMRI," said William S. Marth, President and CEO of AMRI.
- PR Newswire•19 days ago
ALBANY, N.Y., Nov. 14, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI), a premier contract services provider to the life sciences industry, will be presenting two posters at the 2016 AAPS Annual Meeting and Exposition, ...
- Associated Press•25 days ago
The Albany, New York-based company said it had a loss of 57 cents per share. Earnings, adjusted for one-time gains and costs, came to 17 cents per share. The results beat Wall Street expectations. The ...
AYM.F : Summary for ALBANY MOLECULAR DL-,01 - Yahoo Finance
Albany Molecular Research, Inc. (AYM.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 9:54 AM EST
|Bid||15.15 x 26300|
|Ask||15.45 x 25300|
|Day's Range||15.28 - 15.28|
|52 Week Range||11.71 - 16.22|
|PE Ratio (TTM)||-10.46|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|